2009年至2011年我院口服降糖药应用分析  

Application of Oral Hypoglycemic Drugs in Our Hospital between 2009 and 2011

作　　者：谢梅[1] 胡正波[1] 徐春红[1] 徐力[1] 

机构地区：[1]中国人民解放军第452医院药剂科,四川成都610021

出　　处：《中国药业》2013年第16期61-62,共2页China Pharmaceuticals

摘　　要：目的了解医院口服降糖药的使用情况,为临床应用提供参考。方法以销售金额和用药频度(DDDs)、限定日费用(DDC)对医院2009年至2011年口服降糖药进行分类统计、综合分析。结果各年度口服降糖药的用药金额和DDDs均呈现增长趋势,胰岛素增敏药用量呈下降趋势。销售金额排序前2位的始终是瑞格列奈和阿卡波糖,DDDs排序前2位的始终是二甲双胍、瑞格列奈。结论该院口服降糖药临床使用基本合理。Objective To investigate the utilization of oral hypoglyeemic drugs to provide reference for rational clinical use of drugs. Methods The sales amount, DDDs and DDC were adopted to conduct the classified statistic and the comprehensive analysis on the utilization of oral hypoglycemic drugs between 2009 and 2011. Results The sales amount and DDDs of oral hypoglycemic drugs in our hospital were increasing. The consumption quantity of insulin sensitizing agents were decreasing. The sales amount of nepaglinide and acarbose always occupied the first and second place. Metformin and nepaglinide always were the first and the second place in the DDDs ranking. Conclusion The clinical use of oral hvDoglvcemic druzs in our hospital is basicallv rational.

关 键 词：口服降糖药 用药分析 用药频度 限定日费用 

分 类 号：F407.7[经济管理—产业经济] R969.3[医药卫生—药理学]